Why use telmisartan in patients with diabetes and microalbuminuria? Artykuł przeglądowy

##plugins.themes.bootstrap3.article.sidebar##

Dostęp przez subskrypcję PDF (English)


Opublikowane: cze 30, 2016
Słowa kluczowe:
hypertension, diabetes, nephropathy, microalbuminuria, hypotensive treatment, ARB, telmisartan

##plugins.themes.bootstrap3.article.main##

Marek Chmielewski
Department and Clinic of Cardiology, Arterial Hypertension and Internal Medicine, Second Faculty of Medicine, Warsaw Medical University
Marek Kuch
Department and Clinic of Cardiology, Arterial Hypertension and Internal Medicine, Second Faculty of Medicine, Warsaw Medical University

Abstrakt

Efficacy of telmisartan in diabetic nephropathy prevention and microalbuminuria reduction has been established in INNOVATION and ONTARGET studies. Long-term use of high dose of 80 mg telmisartan daily leads to inhibition of clinically overt nephropathy in 33% of patients with type 2 diabetes and microalbuminuria.

##plugins.themes.bootstrap3.article.details##

Jak cytować
Chmielewski , M., & Kuch, M. (2016). Why use telmisartan in patients with diabetes and microalbuminuria?. Medycyna Faktów , 9(2(31), 97-99. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2241
Numer
Tom 9 Nr 2(31) (2016)
Dział
Artykuły

Copyright © by Medical Education. All rights reserved.

Bibliografia

1. Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego 2015; 1(1): 1-70.
2. Yusuf S, Teo KK, Pogue J et al; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
3. Makino H, Haneda M, Babazono T et al. Innovation Study on telmisartan, prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30(6): 1577-1578.